Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) EBIT Margin (2016 - 2020)

Syndax Pharmaceuticals (SNDX) has disclosed EBIT Margin for 6 consecutive years, with 5226.32% as the latest value for Q4 2020.

  • For Q4 2020, EBIT Margin fell 148816.0% year-over-year to 5226.32%; the TTM value through Dec 2020 reached 4708.17%, down 91523.0%, while the annual FY2025 figure was 158.45%, 127598.0% up from the prior year.
  • EBIT Margin hit 5226.32% in Q4 2020 for Syndax Pharmaceuticals, roughly flat from 5238.26% in the prior quarter.
  • Across five years, EBIT Margin topped out at 1633.61% in Q4 2017 and bottomed at 5238.26% in Q3 2020.
  • Average EBIT Margin over 5 years is 4195.8%, with a median of 4351.46% recorded in 2017.
  • Year-over-year, EBIT Margin skyrocketed 2976918bps in 2016 and then tumbled -345402bps in 2018.
  • Syndax Pharmaceuticals' EBIT Margin stood at 3652.79% in 2016, then skyrocketed by 55bps to 1633.61% in 2017, then crashed by -211bps to 5087.63% in 2018, then increased by 27bps to 3738.16% in 2019, then crashed by -40bps to 5226.32% in 2020.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 5226.32%, 5238.26%, and 4382.59% for Q4 2020, Q3 2020, and Q2 2020 respectively.